TSXV - Delayed Quote CAD

Arch Biopartners Inc. (ARCH.V)

1.7200

+0.0200

+(1.18%)

At close: May 9 at 3:54:42 PM EDT

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With this ethics approval in place and all training and preparation

GlobeNewswire 18 days ago

ACHFF
Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed a non-brokered private placement offering of 145,000 common shares priced at CAD $1.55 per common share and 90,000 common shares priced at USD $1.15 (the “Common Shares”) for total gross proceeds of CAD $374,000 (the “Offering”). The final amount of the Offering was an increase of CAD $24,000 from the amount originally disclosed to the mar

GlobeNewswire last month

ACHFF
Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 225,806 common shares priced at $1.55 per common share (the “Common Shares”) for gross proceeds of $350,000 CAD (the “Offering”). The proceeds of the Offering will be used by Arch as general working capital and for certain expenses that are not covered by the Company’s existing funding grants.

GlobeNewswire 2 months ago

ACHFF
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the clinical team leading the upcoming investigator-led trial, titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTiAK), has received a No Objection Letter (NOL) from Health Canada to proceed with the trial. PONTiAK is a 700-patient Phase II trial (revised from 900 patients) evaluating the efficacy of cilastatin in

GlobeNewswire 2 months ago

ACHFF
Shares for Interest Debt Settlement

TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $57,246.57 in interest accrued up to February 1, 2025 on the one remaining deferred convertible note outstanding and disclosed in the Company’s financial statements for the year ended September 30, 2024 (the “Note”). The shares for debt settlement is pending final app

GlobeNewswire 3 months ago

ACHFF
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics Board, through the Clinical Trials Ontario Streamlined Research Ethics Review System, has granted provincial ethics approval for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical teams at Toronto General

GlobeNewswire 3 months ago

ACHFF
Arch Biopartners doses first subject in trial of acute kidney injury treatment

The multicentre, placebo-controlled trial aims to recruit 240 participants in total.

Clinical Trials Arena 5 months ago

ACHFF
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of Calgary Cumming School of Medicine has started screening patients for the trial and has completed dosing of the first

GlobeNewswire 5 months ago

ACHFF
Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that was previously announced on September 26, 2024 to settle an aggregate total of $2,600,000 of principal plus accrued interest of $130,000 on four deferred convertible notes maturing on Sept 30, 2024 (the “Notes”). The original terms of the four Notes included settlement of the principal owing with 3,220,147

GlobeNewswire 7 months ago

ACHFF
Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to settle an aggregate total of $2,600,000 of principal plus accrued interest owing on four deferred convertible notes maturing on Sept 30, 2024 (the “Notes”). The original terms of the four Notes included settlement of the principal owing with 3,220,147 common shares priced at a weighted average of $0.81. In

GlobeNewswire 7 months ago

ACHFF
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of Calgary Cumming School of Medicine is now completing final preparations and training to enable the start of patient recruitment in

GlobeNewswire 7 months ago

ACHFF
Arch Biopartners’ cilastatin enters Phase II trial for AKI prevention

The Universities of Calgary and Alberta-based clinical team received $1.5m funding from CIHR for the trial.

Clinical Trials Arena 8 months ago

ACHFF
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissueArch continues to perform a Phase II trial for LSALT peptide targeting cardiac surgery-associated-AKI Drug toxins and CS-AKI account for up to 50% of all AKI occurring in hospitals, for which there is no treatment available TORONTO, A

GlobeNewswire 9 months ago

ACHFF
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for cilastatin, the Company’s second drug candidate for preventing acute kidney injury (AKI). Over the next six to eight weeks Dalton will be completing the quality control process which will culminate with the release of a first-ever, stand-alon

GlobeNewswire 10 months ago

ACHFF
Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial

Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial

PREMIUM
MT Newswires 10 months ago

ACHFF
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of Calgary Cumming School of Medicine is now able to work with Arch to complete preparatio

GlobeNewswire 10 months ago

ACHFF

Performance Overview

Return	ARCH.V	S&P/TSX Composite index (^GSPTSE)
YTD	-6.52%	+2.99%
1-Year	+1.18%	+13.33%
3-Year	-55.44%	+26.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arch Biopartners Inc. (ARCH.V)

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

Shares for Interest Debt Settlement

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners doses first subject in trial of acute kidney injury treatment

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners’ cilastatin enters Phase II trial for AKI prevention

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Performance Overview